Global Partners L.P. (GLP)
NYSE NYSE Primary 
Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients
Positive 12-week data from phase 2a study of GSBR-1290 targeting obesity patients; significant placebo adjusted mean weight loss of 6.2% & 6.9% achieved for capsule and tablet respectively. One analyst believes that the market for obesity treatments could expand to $200 billion by 2031. The 36-week phase 2b study, using GSBR-1290 for the treatment of patients with obesity, expected to start in Q4 of 2024.
Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received partial 12-week (final) body weight results from the recently completed animal study WEIGHT-A24-1 (the "Study").
1 Healthcare Giant That Isn't Jumping on the GLP-1 Bandwagon, and Why That Could Be a Great Move
Novartis is taking a more calculated and strategic approach to its growth.
GLP-1 Stocks Aren't the Only Way to Benefit From the Weight Loss Drugs Boom
The future of the weight loss market might not revolve around GLP-1 drugs.
WeightWatchers stock price skyrockets on news that it will offer a compounded GLP-1 weight-loss drug like Wegovy
WeightWatchers announced on Tuesday that it will offer a compounded version of Novo Nordisk‘s popular weight-loss drug Wegovy as part of its weight-management programs, a move that sent its shares soaring nearly 47%.
Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing
DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format KELOWNA, BC / ACCESSWIRE / October 9, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that dosing has begun, for human pilot study #3 (the "Study"), investigating a DehydraTECH-processed version of the dual action GLP-1 (glucagon-like peptide) + GIP (glucose-dependent insulinotropic peptide) Zepbound® (tirzepatide) in an oral dose format. The Study is being conducted in up to 10 healthy volunteers.
WeightWatchers' stock soars after adding compounded GLP-1 treatment to its offering
“With the addition of compounded semaglutide [GLP-1], we are expanding our offering to include a clinical weight management solution that is both accessible and affordable,” said Interim Chief Executive Tara Comonte in prepared remarks.
GLP Capital Partners and Ares Management Corp to Merge in $5.2 Billion Deal
GLP Group has announced the merger of its fund management business, GLP Capital Partners (GCP), with Ares Management Corporation, a leading alternative asset management company listed on the New York Stock Exchange. The merger includes GCP's international operations in Japan, the United States, Europe, Brazil, and Vietnam.
Lexaria Updates Current GLP-1 Market
KELOWNA, BC / ACCESSWIRE / October 8, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery technology, provides an update on recent glucagon-like peptide-1 ("GLP-1") receptor agonist market sector advancements. In 2020 the total market size for GLP-1 drugs was less than $4 billion.
Concerns Over Muscle Loss with GLP-1 Weight Loss Drugs (LLY, NVO, REGN)
Clinical studies highlight that Eli Lilly (LLY, Financial) and Novo Nordisk's (NVO) weight loss drugs result in significant lean body mass reduction, with 25% and 40% of weight loss attributed to muscle loss, respectively. In response, Regeneron (REGN) is researching a new drug aimed at mitigating muscle loss caused by weight loss medications.
Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data
Viking Therapeutics, Inc. stock has surged nearly 1,500% since 2023, driven by the promising GLP-1/GIP receptor agonist VK-2735 for obesity. VK-2735's Phase 2 data showed weight loss comparable to Novo Nordisk's Wegovy and Eli Lilly's Zepbound, pitching it to one day compete in a >$150bn market. Viking's strong financial position, upcoming Phase 3 trials, and potential oral formulation of VK-2735 justify upgrading the stock to a “Buy.”.
GLP-1 demand is going to remain higher than supply for foreseeable future, says BMO's Evan Seigerman
Evan Seigerman, BMO senior analyst, joins 'Closing Bell Overtime' to talk today's Capitol Hill hearing with Novo Nordisk's CEO and the demand for weight-loss drugs.
